One Size Can Fit All: AlloCell – the Universal Assay for Pharmacokinetics (PK) Monitoring of Allogeneic Cell Therapies
Pharmacokinetic monitoring of cell therapies requires laborious development of bespoke, drug product-specific assays. Every new product or significant modification can send teams back to the starting line, and resulting assays often cannot be utilized across an entire pipeline, making it difficult to compare patient results across different drug products.
AlloCell offers a universal PK monitoring solution for allogeneic cell therapies. With validated high sensitivity and reproducibility, AlloCell is a ready-to-use solution with end-to-end sample-to-results service, applicable to any allogeneic cell therapy, regardless of the modality (T cell, NK cell, macrophage, etc.) and agnostic to genome engineering details.
Please join us on October 19th to learn more about AlloCell, as well as its family of products: AlloCell cfDNA, AutoCell, AlloHeme, and CareDx’s HLA typing solution—AlloSeq Tx17—all designed to help accelerate your drug development journey.
Pharmacokinetic monitoring of cell therapies requires laborious development of bespoke, drug product-specific assays. Every new product or significant modification can send teams back to the starting line, and resulting assays often cannot be utilized across an entire pipeline, making it difficult to compare patient results across different drug products.
AlloCell offers a universal PK monitoring solution for allogeneic cell therapies. With validated high sensitivity and reproducibility, AlloCell is a ready-to-use solution with end-to-end sample-to-results service, applicable to any allogeneic cell therapy, regardless of the modality (T cell, NK cell, macrophage, etc.) and agnostic to genome engineering details.
Please join us on October 19th to learn more about AlloCell, as well as its family of products: AlloCell cfDNA, AutoCell, AlloHeme, and CareDx’s HLA typing solution—AlloSeq Tx17—all designed to help accelerate your drug development journey.
One Size Can Fit All: AlloCell – the Universal Assay for Pharmacokinetics (PK) Monitoring of Allogeneic Cell Therapies
Pharmacokinetic monitoring of cell therapies requires laborious development of bespoke, drug product-specific assays. Every new product or significant modification can send teams back to the starting line, and resulting assays often cannot be utilized across an entire pipeline, making it difficult to compare patient results across different drug products.
AlloCell offers a universal PK monitoring solution for allogeneic cell therapies. With validated high sensitivity and reproducibility, AlloCell is a ready-to-use solution with end-to-end sample-to-results service, applicable to any allogeneic cell therapy, regardless of the modality (T cell, NK cell, macrophage, etc.) and agnostic to genome engineering details.
Please join us on October 19th to learn more about AlloCell, as well as its family of products: AlloCell cfDNA, AutoCell, AlloHeme, and CareDx’s HLA typing solution—AlloSeq Tx17—all designed to help accelerate your drug development journey.
CareDx offers a suite of products designed to help accelerate your drug development journey
AlloCell is a universal PK monitoring solution for allogeneic cell therapies, that is ready-to-use on day one, without the need for customization or development
AlloCell can help you achieve the sensitivity, reproducibility, and comparability you have been looking for, across all of your allogeneic drug products
